Blood clues may unlock mystery of brittle bone disease severity
NCT ID NCT04009733
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study looked at 66 adults with Osteogenesis Imperfecta (brittle bone disease) to see if small molecules called microRNAs in the blood are linked to how severe the condition is. Researchers compared people with mild (type 1) and severe (type 3) forms, plus healthy controls. The goal was to find patterns that could explain why the same genetic mutation leads to very different outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could help identify biological markers that predict disease severity, potentially guiding future treatments.
- What could go wrong
- This is an observational study, not a treatment trial. It is small (66 participants) and only looks at correlations, not causes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOGENESIS IMPERFECTA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hôpital Edouard Herriot
Lyon, 69003, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Dental scans and AI could spot rare bone diseases faster
- Wearable sensors shed light on movement in brittle bone disease
- BONeMOVE: exercise boosts stamina in kids with brittle bones
- Massive database aims to unlock secrets of facial birth defects
- Radiation-Free bone scan tested in kids
- New nail tested for kids with brittle bones